Mouse Orm2 ELISA Kit (V2LY-0626-LY3324)

Lee, S. H., Suh, J. H., Heo, M. J., Choi, J. M., Yang, Y., Jung, H. J., ... & Kim, K. H. (2024). The hepatokine orosomucoid 2 mediates beneficial metabolic effects of bile acids. Diabetes, db230520.

Wei, X., Wang, L., Yang, B., Ma, Y., Yuan, W., & Ma, J. (2024). Orosomucoid 2 upregulation mediates liver injury‐induced colorectal cancer liver metastasis by promoting EMT and cell migration. Cancer Science.

Li, L., Sun, H., Chen, J., Ding, C., Yang, X., Han, H., & Sun, Q. (2023). Mitigation of non-alcoholic steatohepatitis via recombinant Orosomucoid 2, an acute phase protein modulating the Erk1/2-PPARγ-Cd36 pathway. Cell Reports, 42(7).

Zhou, B., Luo, Y., Ji, N., Hu, C., & Lu, Y. (2022). Orosomucoid 2 maintains hepatic lipid homeostasis through suppression of de novo lipogenesis. Nature Metabolism, 4(9), 1185-1201.

Zhu, H. Z., Zhou, W. J., Wan, Y. F., Ge, K., Lu, J., & Jia, C. K. (2020). Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer. World journal of gastroenterology, 26(8), 804.

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols